Medication-induced movement disorders sit at the intersection of psychiatry, neurology, and emergency medicine, and they remain among the most clinically consequential adverse effects of psychotropic prescribing. DSM-5-TR groups these conditions in a dedicated chapter (Medication-Induced Movement Disorders and Other Adverse Effects of Medication) because, while not mental disorders themselves, they are routinely encountered, frequently misattributed, and central to risk-benefit decisions in long-term care. The syndromes span an acute-to-chronic continuum: acute dystonia and akathisia appear within hours to weeks, drug-induced parkinsonism over weeks to months, and tardive syndromes after months to years of cumulative exposure. Two are time-critical emergencies — Neuroleptic Malignant Syndrome and Serotonin Syndrome — and confusing them carries direct mortality. The clinical bottom line is simple: every psychotropic prescription is a longitudinal commitment to surveillance, because the cheapest way to treat a movement disorder is to recognize it early and adjust before it becomes irreversible.

Medication-induced movement disorders are common enough that any prescriber of antipsychotics will encounter them, with rates varying sharply by drug class, dose, duration, and patient age. The single largest determinant remains exposure to dopamine receptor blocking agents — both first-generation antipsychotics (FGAs) and, to a lesser but non-trivial extent, second-generation antipsychotics (SGAs).

Prevalence by syndrome

• Acute dystonic reactions occur in roughly 3-10% of patients started on high-potency FGAs, with most events in the first 5 days of exposure.^[1-2]
• Akathisia affects 20-35% of antipsychotic-treated patients across pooled samples, with higher rates on high-potency FGAs and several SGAs including aripiprazole and lurasidone.^[1,3]
• Drug-induced parkinsonism develops in 15-40% of antipsychotic-treated patients depending on agent and age, and is the most common cause of new parkinsonism in older adults presenting to psychiatric services.^[1,4]
• Tardive Dyskinesia (TD) has an annual incidence of approximately 5% per year of FGA exposure and roughly 3% per year on SGAs, with cumulative prevalence reaching 20-30% after years of treatment.^[1,5]
• Neuroleptic Malignant Syndrome (NMS) occurs in roughly 0.01-0.02% of antipsychotic-exposed patients in modern cohorts, with case-fatality of 5-20% depending on recognition.^[1,6]
• Serotonin syndrome is reported in up to 14-16% of patients with SSRI overdose; incidence in therapeutic use is much lower but rises with serotonergic polypharmacy.^[7]

Demographic risk factors

• Acute dystonia: young, male, antipsychotic-naive, high-potency dopamine antagonist, parenteral route.^[1-2]
• Tardive dyskinesia: older age, female sex (postmenopausal), African ancestry, mood disorder diagnosis, intermittent dosing, early Extrapyramidal Symptoms, diabetes, and cumulative antipsychotic exposure.^[5,8]
• NMS: rapid dose escalation, parenteral high-potency agents, dehydration, agitation, restraint, prior NMS episode, and male sex.^[6]
• Serotonin syndrome: combination of two or more serotonergic agents, particularly an SSRI/SNRI with an MAOI, linezolid, tramadol, methylene blue, or MDMA.^[7,9]

The movement disorders share a common pharmacologic root — disruption of dopamine signaling in the nigrostriatal pathway — but diverge sharply in the temporal pattern and circuit-level reorganization that produce each syndrome. Serotonin syndrome and NMS, while clinically adjacent, arise from distinct neurotransmitter mechanisms and should not be reasoned about as variants of the same process.

Dopamine blockade and the Nigrostriatal Pathway

• Acute D2 receptor blockade in the striatum produces a cholinergic-dopaminergic imbalance, generating acute dystonia and parkinsonism via disinhibition of striatal cholinergic interneurons.^[1,3]
• Threshold for parkinsonism is approximately 70-80% striatal D2 occupancy on PET imaging, the same range that drives antipsychotic efficacy — explaining the narrow therapeutic window of high-potency FGAs.^[3]
• Akathisia is less well-localized; current models implicate mesocortical dopamine blockade, descending noradrenergic dysregulation, and disturbed iron handling in the substantia nigra.^[3-4]

Tardive dyskinesia mechanisms

• The classical model posits postsynaptic D2 receptor supersensitivity from chronic blockade, leading to upregulated and hypersensitive striatal receptors that produce involuntary movements when dopamine signaling fluctuates.^[5,8]
• Newer models emphasize oxidative stress, GABAergic interneuron loss in the striatum, and aberrant synaptic plasticity, consistent with the partial irreversibility of the syndrome.^[5,8]
• Genetic associations include polymorphisms in DRD2, DRD3 (Ser9Gly), COMT, and CYP2D6 poor-metabolizer status, though none is clinically actionable for screening.^[5,8]

NMS pathophysiology

• The dominant model is acute central dopaminergic hypofunction across nigrostriatal, mesolimbic, and hypothalamic pathways, producing rigidity, autonomic instability, and hyperthermia respectively.^[6,13]
• A skeletal-muscle hypothesis posits a direct effect of antipsychotics on calcium handling in muscle, supported by partial response to dantrolene and overlap with malignant hyperthermia susceptibility.^[6,13]
• NMS has been reported with every antipsychotic including clozapine, and with abrupt withdrawal of dopaminergic agents in Parkinson disease.^[6]

Serotonin syndrome pathophysiology

• Excess agonism at central 5-HT2A and 5-HT1A receptors drives the triad of mental status change, autonomic hyperactivity, and neuromuscular excitation.^[7,9]
• Onset is typically within 24 hours of the offending combination or dose change, contrasting with the days-to-weeks tempo of NMS.^[7,9]

DSM-5-TR organizes these conditions in a dedicated chapter that follows the substance-related and other neurodevelopmental sections, recognizing that they require clinical attention even when no mental disorder is present. The criteria are pragmatic rather than research-grade, anchored to temporal association with the offending agent and exclusion of competing causes.

Medication-induced acute dystonia

• Abnormal and prolonged contraction of muscles of the eyes (oculogyric crisis), head, neck (torticollis, retrocollis), limbs, or trunk developing within days of starting or raising the dose of a dopamine antagonist, or reducing an antiparkinsonian medication.^[14]
• Laryngeal dystonia is the rare but life-threatening form because airway compromise can occur within minutes.^[1-2]

Medication-induced acute akathisia

• Subjective complaint of restlessness, frequently accompanied by observed restlessness (pacing, rocking, inability to sit still), developing within weeks of antipsychotic initiation, dose increase, or reduction of an anticholinergic.^[14]
• Severity is graded on the Barnes Akathisia Rating Scale, with separate subjective, objective, and global ratings.^[3,15]

Medication-induced parkinsonism

• Parkinsonian tremor, rigidity, akinesia/bradykinesia developing within a few weeks of initiating or raising the dose of a medication (typically a dopamine antagonist) or reducing the dose of a medication used to treat extrapyramidal symptoms.^[14]
• Symptoms are typically symmetric at onset, in contrast to the asymmetric onset of idiopathic Parkinson disease.^[4,16]

Tardive syndromes

• Tardive dyskinesia: involuntary athetoid or choreiform movements of the tongue, jaw, trunk, or extremities developing in association with the use of a dopamine antagonist for at least a few months (or shorter in older adults), and persisting at least 4-8 weeks after the offending agent is stopped or changed.^[14]
• The DSM-5-TR umbrella also covers tardive dystonia, tardive akathisia, and tardive tic, distinguished by phenomenology and time course.^[5,14]

Neuroleptic Malignant Syndrome

• Severe muscle rigidity and elevated temperature developing in association with the use of antipsychotic medication, accompanied by two or more of: diaphoresis, dysphagia, tremor, incontinence, altered consciousness, mutism, tachycardia, blood pressure elevation or lability, leukocytosis, or laboratory evidence of muscle injury (CK elevation).^[6,14]
• The International Expert Consensus Panel proposed operationalized criteria including exposure within 72 hours, hyperthermia >100.4 F (38 C) on at least two occasions, rigidity, mental status change, CK elevation >4x upper limit, autonomic dysfunction, and hypermetabolic state (tachycardia plus tachypnea).^[6,17]

Medication-induced postural tremor

• Fine postural tremor temporally associated with use of medications including lithium, valproate, SSRIs, beta-agonists, and stimulants, in the absence of better explanation.^[14,18]

ICD-11 differences

• ICD-11 codes these conditions under "Disorders due to substance use or addictive behaviours" and the neurology chapter rather than under mental disorders, which is occasionally relevant for billing and registry research but does not change clinical management.^[19]

Each syndrome has a characteristic tempo and phenomenology, and the cardinal clinical skill is matching presentation to time course to determine likely cause and reversibility. The same patient may carry overlapping syndromes (parkinsonism plus akathisia is common), and one syndrome may mask another (parkinsonian bradykinesia can hide tardive dyskinesia until the antipsychotic is reduced).

Acute dystonia

• Onset usually 12 hours to 5 days after antipsychotic initiation; >90% of cases occur within 5 days.^[1-2]
• Classic presentations include torticollis, retrocollis, opisthotonos, oculogyric crisis (sustained upward eye deviation), trismus, and tongue protrusion.^[2]
• Laryngeal-pharyngeal dystonia presents as stridor, dyspnea, or dysphagia and is a medical emergency.^[2]

Akathisia

• Patients describe inner restlessness as "jumping out of my skin," inability to sit, urge to walk; observed signs include leg crossing/uncrossing, rocking, marching in place, and shifting weight when standing.^[3,15]
• Akathisia is frequently misdiagnosed as worsening psychosis or agitation, leading to dose increases that worsen the syndrome — one of the most important clinical traps in psychopharmacology.^[3]
• Associations with suicidal ideation and aggression have been reported in case series, reinforcing the urgency of recognition.^[3,20]

Drug-induced parkinsonism

• Bradykinesia, cogwheel rigidity, masked facies, and a symmetric resting/postural tremor; gait shows reduced arm swing but preserved postural reflexes more often than in idiopathic Parkinson disease.^[4,16]
• Resolution typically occurs over weeks to months after dopamine antagonist withdrawal; persistent parkinsonism after 6 months suggests unmasked idiopathic Parkinson disease.^[4]

Tardive dyskinesia

• Stereotyped, repetitive choreoathetoid movements of the orobuccolingual region (chewing, lip-smacking, tongue protrusion, grimacing); trunk and limb involvement occurs in more severe cases.^[5,8]
• Movements worsen with emotional arousal, abate during sleep, and can be transiently suppressed by voluntary effort.^[5]
• Dose reduction or discontinuation of the offending agent transiently worsens the movements ("withdrawal-emergent dyskinesia") in many patients before improvement begins.^[5,8]

Neuroleptic Malignant Syndrome

• Classic tetrad: hyperthermia, severe "lead-pipe" rigidity, autonomic instability, and altered mental status.^[6,13]
• Onset is typically days to 2 weeks after initiation or dose escalation; rigidity precedes hyperthermia in most cases.^[6]
• Laboratory hallmarks: CK frequently >1,000 U/L (often >10,000), leukocytosis 10,000-40,000, metabolic acidosis, transaminase elevation, and myoglobinuria with risk of acute kidney injury.^[6,13]

NMS: hyperthermia plus rigidity plus autonomic instability plus altered mental status after dopamine antagonist exposure.^[6]

Serotonin syndrome

• Sternbach triad and Hunter criteria emphasize spontaneous clonus, inducible clonus with agitation/diaphoresis, ocular clonus, tremor with hyperreflexia, or hypertonia with hyperthermia >38 C and ocular/inducible clonus.^[7,9]
• Neuromuscular features are predominantly lower-extremity ("clonus from the knees down"), in contrast to the diffuse rigidity of NMS.^[7,9]
• Onset is typically within 6-24 hours of the offending dose change or combination.^[7,9]

Distinguishing medication-induced movement disorders from primary neurologic disease and from each other is among the highest-yield bedside skills in psychiatry. The differential is anchored to time course, symmetry, accompanying autonomic features, and the specific phenomenology of the movement.

NMS versus serotonin syndrome

• Causative agent: dopamine antagonist (or dopamine-agonist withdrawal) versus serotonergic agent or combination.^[6-7]
• Onset: days to 2 weeks versus hours.^[6-7]
• Neuromuscular: diffuse "lead-pipe" rigidity, hyporeflexia versus lower-extremity-predominant clonus, hyperreflexia, myoclonus.^[7,9]
• Pupils: normal or sluggish versus mydriasis.^[7]
• Bowel sounds: normal/decreased versus hyperactive.^[7]
• Skin: pallor and diaphoresis versus diaphoresis with flushing.^[7]

Other differentials by syndrome

• Acute dystonia versus focal seizure, tetanus, strychnine poisoning, conversion disorder; resolution with parenteral anticholinergic strongly supports acute dystonia.^[1-2]
• Drug-induced parkinsonism versus idiopathic Parkinson disease, vascular parkinsonism, normal-pressure hydrocephalus, progressive supranuclear palsy; symmetry, exposure history, and DaT-SPECT (when available) help.^[4,16]
• Tardive dyskinesia versus Huntington disease, Wilson disease, Sydenham chorea, edentulous orobuccal movements, stereotypies of intellectual disability; family history, copper studies, and exposure history disambiguate.^[5,8]
• Akathisia versus restless legs syndrome (worse at night, relieved by movement in bed, dopamine-agonist responsive), agitated depression, anxiety, and stimulant-induced restlessness.^[3,15]
• Postural tremor (lithium, valproate, SSRIs) versus essential tremor, hyperthyroidism, alcohol withdrawal, cerebellar tremor.^[18]

Medical mimics not to miss

• Hyperthyroidism (tremor, agitation), pheochromocytoma (paroxysmal autonomic surge), CNS infection (meningitis/encephalitis with fever and altered mental status), sepsis, heat stroke, and nonconvulsive status epilepticus.^[6-7]

Assessment hinges on a careful drug exposure timeline, a standardized motor examination, and targeted laboratory work. The single most informative datum is often the dose and date of every dopaminergic or serotonergic agent in the preceding 90 days, including injectables and over-the-counter compounds.

History

• Complete medication reconciliation including long-acting injectables, recently discontinued agents, antiemetics (metoclopramide, prochlorperazine), and herbal/OTC products.^[1,5]
• Time course of motor symptoms relative to each exposure or dose change, including taper of antiparkinsonian medications.^[14]
• Personal and family history of movement disorders, NMS, malignant hyperthermia, and dystonia.^[6,13]

Examination

• Standardized assessment using the Abnormal Involuntary Movement Scale (AIMS) for tardive dyskinesia, the Barnes Akathisia Rating Scale for akathisia, and the Simpson-Angus Scale for parkinsonism.^[15,22]
• Document baseline AIMS before initiating any antipsychotic and at least every 6 months on FGAs, every 12 months on SGAs, and more frequently in higher-risk populations.^[1,5]
• Vital signs including continuous temperature monitoring in any suspected NMS or serotonin syndrome presentation.^[6-7]

Laboratories and imaging

• Suspected NMS: CBC, comprehensive metabolic panel, CK, urinalysis with myoglobin, coagulation studies, ABG, and infectious workup including blood cultures and lumbar puncture when meningitis cannot be excluded.^[6,13]
• Suspected serotonin syndrome: similar metabolic panel plus drug screen; CK is typically elevated less dramatically than in NMS.^[7]
• Lithium tremor: serum lithium level, TSH, BUN/creatinine, electrolytes.^[18,23]
• New parkinsonism in older adults on antipsychotics: re-examine 3-6 months after dose reduction; consider DaT-SPECT if symptoms persist to distinguish idiopathic Parkinson disease.^[4,16]

What not to order

• Routine neuroimaging in uncomplicated drug-induced parkinsonism, acute dystonia, or akathisia adds nothing and delays treatment.^[4]
• Genetic testing for tardive dyskinesia susceptibility is not clinically indicated outside of research.^[5,8]

Management starts with risk-stratified prevention — choosing lower-EPS-risk agents in vulnerable patients, using the minimum effective dose, and surveilling actively. Once a syndrome appears, treatment is syndrome-specific, and reflexive responses ("add an anticholinergic") can worsen the wrong condition.

Pharmacotherapy

• Acute dystonia: parenteral anticholinergic such as benztropine 1-2 mg IM or IV or diphenhydramine 25-50 mg IM or IV, with repeat dosing in 20-30 minutes if no response; continued oral anticholinergic cover for 24-72 hours after the dopamine antagonist is continued.^[1-2]
• Akathisia: reduce the offending dose if possible; first-line pharmacotherapy is propranolol 10-20 mg PO TID titrated as tolerated; second-line options include mirtazapine, low-dose benzodiazepines (lorazepam, clonazepam), and 5-HT2A antagonists.^[3,15]
• Drug-induced parkinsonism: reduce or switch the dopamine antagonist (prefer quetiapine or clozapine in vulnerable patients); add an anticholinergic such as benztropine 0.5-2 mg PO BID only when dose reduction is insufficient and the patient is not elderly.^[1,4]
• Tardive dyskinesia: switch to a lower-risk antipsychotic where clinically possible; VMAT2 inhibitors are the only FDA-approved treatments — valbenazine 40-80 mg PO QD and deutetrabenazine 12-48 mg PO BID with food.^[5,24-25]
• NMS: stop the antipsychotic immediately, aggressive supportive care (cooling, fluids, electrolyte correction, prophylaxis for DVT and rhabdomyolysis); pharmacologic adjuncts include bromocriptine 2.5-10 mg PO q8h, dantrolene 1-2.5 mg/kg IV, and lorazepam for catatonic features.^[6,13]
• Serotonin syndrome: stop all serotonergic agents, supportive care; for moderate-to-severe cases use cyproheptadine 12 mg PO load then 2 mg q2h until response, then 8 mg q6h.^[7,9]
• Medication-induced postural tremor (lithium, valproate): dose reduction is first; if continued, propranolol 10-40 mg PO TID reduces tremor amplitude.^[18]

Psychotherapy

• Formal psychotherapy is not a primary treatment for these syndromes but is essential for adherence support, particularly when antipsychotic continuation is necessary despite distressing motor side effects.^[1]
• Psychoeducation about realistic timeframes for resolution (weeks to months for parkinsonism, potentially permanent for tardive dyskinesia) is part of informed consent and a defense against premature self-discontinuation.^[5]

Neuromodulation

• Deep brain stimulation of the globus pallidus interna has limited evidence in severe, refractory tardive dystonia and dyskinesia; case series and small RCTs show meaningful motor improvement.^[26]
• Electroconvulsive therapy has been reported as effective in NMS, particularly when catatonic features dominate or pharmacologic treatments fail; evidence is limited to case series and small retrospective studies.^[27]

Adjunctive

• Vitamin E was studied for tardive dyskinesia in older trials; current evidence does not support clinically meaningful benefit, and it should not delay VMAT2 inhibitor initiation.^[5,24]
• Ginkgo biloba extract has shown small benefits for tardive dyskinesia in trials in chronic schizophrenia; limited evidence and product variability limit recommendation.^[5]
• Switching to clozapine has the strongest evidence for reducing tardive dyskinesia severity while continuing antipsychotic treatment, balanced against agranulocytosis risk and monitoring burden.^[5,28]

Every intervention for medication-induced movement disorders carries its own side-effect profile, and the evidence base for several long-standing practices is thinner than guideline confidence implies. The clinician balances acute relief against longer-term risks, often in patients whose underlying illness limits the option of withdrawing the offending agent altogether.

Common adverse effects

• Anticholinergics: dry mouth, blurred vision, constipation, urinary retention, cognitive impairment in older adults.^[1,29]
• Beta-blockers: bradycardia, hypotension, fatigue, bronchospasm in reactive airway disease.^[3]
• VMAT2 inhibitors: somnolence, fatigue, mild parkinsonism, QT prolongation; tetrabenazine carries a black-box warning for depression and suicidality, with milder signal for valbenazine and deutetrabenazine.^[24-25]
• Bromocriptine: hypotension, nausea, psychosis exacerbation in patients with active psychotic illness.^[6]
• Dantrolene: hepatotoxicity with cumulative dosing, muscle weakness, phlebitis.^[6,13]

Serious or rare adverse effects

• Anticholinergic delirium and falls in older adults; this is the most common preventable iatrogenic harm in geriatric psychiatry inpatient units.^[29]
• NMS recurrence with antipsychotic rechallenge ranges 30-50%; risk is reduced but not eliminated by switching class, waiting at least 2 weeks, and slow titration.^[6]
• Acute kidney injury from rhabdomyolysis in NMS; mortality in undiagnosed cases reflects this complication.^[6,13]
• QTc prolongation with VMAT2 inhibitors, particularly in combination with other QT-prolonging agents.^[24-25]

Monitoring and discontinuation

• Tardive dyskinesia frequently worsens transiently when the offending agent is reduced; warn the patient and the family in advance.^[5]
• Abrupt discontinuation of long-term anticholinergics can precipitate cholinergic rebound (nausea, diarrhea, insomnia) and unmask previously suppressed parkinsonism.^[1]
• Lithium-induced tremor that fails to respond to dose reduction and beta-blockade may signal subclinical toxicity; check levels and renal function rather than titrating tremor therapy.^[18,23]

Limitations of the evidence base

• Most NMS evidence is retrospective; no RCT has compared bromocriptine and dantrolene head-to-head.^[6,13]
• Long-term safety of VMAT2 inhibitors beyond 1-2 years is largely uncharacterized.^[24-25]
• Risk estimates for tardive dyskinesia on newer SGAs (cariprazine, lumateperone) come from short pivotal trials and may underestimate cumulative risk.^[5,8]

Risk and management differ substantially across the lifespan and across comorbid medical illness. The patient who most needs an antipsychotic is often the one least able to tolerate its motor adverse effects, and individualized risk-benefit weighing is the rule rather than the exception.

Pediatric

• Acute dystonia is the most common antipsychotic adverse effect in children and adolescents, with rates higher than in adults at equivalent D2 occupancy.^[1,30]
• Tardive dyskinesia in children is less well-characterized but appears with chronic exposure; cumulative risk argues against indefinite antipsychotic use in non-psychotic indications.^[5,30]
• Withdrawal dyskinesias on antipsychotic taper occur in 25-50% of children and typically resolve within 12 weeks.^[30]

Geriatric

• Older adults have the highest incidence of drug-induced parkinsonism and tardive dyskinesia per unit exposure, driven by age-related dopaminergic neuron loss.^[4-5]
• Anticholinergics carry an unfavorable risk-benefit ratio in this population because of delirium, falls, and dementia-related cognitive vulnerability.^[29]
• Metoclopramide-induced parkinsonism and TD are major iatrogenic problems in geriatric inpatients and long-term care residents; a 12-week prescribing cap is FDA-recommended.^[31]

Perinatal

• Antipsychotic-exposed neonates can present with extrapyramidal and withdrawal signs (tremor, hypertonia, feeding difficulty) requiring monitoring for 48-72 hours after delivery.^[32]
• Lithium tremor in pregnancy is common, and serum levels rise post-partum because of plasma-volume contraction; check levels weekly in the third trimester and immediately post-partum.^[23]

Comorbid medical illness

• Parkinson disease and Lewy body dementia patients are exquisitely sensitive to dopamine blockade; quetiapine and clozapine are preferred, and pimavanserin is FDA-approved for Parkinson disease psychosis.^[33]
• HIV-associated cognitive disorder and traumatic brain injury increase EPS risk at standard antipsychotic doses; start low and titrate slowly.^[1]
• Comorbid epilepsy: most antipsychotics lower seizure threshold; clozapine carries the highest risk in a dose-dependent manner.^[28]

Comorbid substance use

• Stimulant use can mimic akathisia and complicate diagnosis; review urine drug screens before escalating treatment for restlessness.^[3]
• Alcohol withdrawal tremor can be mistaken for medication-induced tremor; the time course and autonomic signs disambiguate.^[18]

Cultural considerations

• African-ancestry patients have higher reported rates of tardive dyskinesia in some cohorts; whether this reflects pharmacogenetics, dosing patterns, or diagnostic bias remains contested.^[5,8]
• Patient reluctance to report subjective restlessness for cultural or stigma-related reasons may underestimate akathisia; objective examination is essential.^[3,15]

Outcomes vary dramatically by syndrome. Acute dystonia and drug-induced parkinsonism are largely reversible; tardive dyskinesia is often partially or fully irreversible; NMS and serotonin syndrome are reversible with timely recognition but lethal when missed.

Reversibility by syndrome

• Acute dystonia: complete resolution within 24-48 hours of treatment in nearly all cases.^[1-2]
• Akathisia: resolution over days to weeks after offending agent reduction or initiation of beta-blocker.^[3,15]
• Drug-induced parkinsonism: gradual improvement over 4-8 weeks after dose reduction; persistence beyond 6 months suggests unmasked idiopathic Parkinson disease and follow-up imaging may be useful.^[4,16]
• Tardive dyskinesia: spontaneous remission rates of 10-25% on continued antipsychotic; higher with switch to lower-risk agent or clozapine; VMAT2 inhibitors provide symptomatic control rather than cure, with benefit waning if discontinued.^[5,24-25]
• NMS: mortality 5-20% with prompt recognition; survivors usually recover fully over 2-4 weeks; cognitive sequelae uncommon but reported.^[6,13]
• Serotonin syndrome: mild cases resolve within 24-72 hours; moderate cases within 1 week; severe cases carry mortality if hyperthermia >40 C is not aggressively managed.^[7,9]

Functional and quality-of-life outcomes

• Tardive dyskinesia is associated with social embarrassment, treatment nonadherence, and reduced quality of life independent of underlying psychiatric illness.^[5,8]
• Akathisia has been linked to medication discontinuation and treatment failure in first-episode psychosis cohorts.^[3]

Mortality

• NMS-attributable mortality has fallen from approximately 30% in the 1970s-80s to 5-10% in modern cohorts, reflecting earlier recognition and improved supportive care.^[6,13]
• Serotonin syndrome severe enough to require ICU admission carries mortality of approximately 2-12% in case series.^[7,9]

Two presentations on this list — NMS and serotonin syndrome — are time-critical medical emergencies, and one (laryngeal dystonia) is an airway emergency. The defining clinical decisions are made in the first hour.

Hospitalization criteria

• Suspected NMS or serotonin syndrome: admit to a setting capable of continuous monitoring, IV access, and rapid response; severe cases require ICU.^[6-7]
• Laryngeal dystonia: emergency department or rapid-response evaluation; do not discharge until airway is secured and the dystonia has fully resolved.^[2]
• Severe acute akathisia with suicidal ideation: inpatient or partial hospitalization until restlessness is controlled.^[3,20]

Acute management priorities

• NMS: discontinue antipsychotic, aggressive cooling, IV fluids targeting urine output >1-2 mL/kg/hr to prevent acute kidney injury, electrolyte correction, DVT prophylaxis once bleeding risk is acceptable.^[6,13]
• Serotonin syndrome: discontinue all serotonergic agents, IV fluids, benzodiazepines for agitation and myoclonus, active cooling for hyperthermia, intubation and neuromuscular blockade for severe hyperthermia >40 C.^[7,9]
• Laryngeal dystonia: IV anticholinergic immediately; prepare for advanced airway management if no response within minutes.^[2]

Agitation management in patients at risk for movement disorders:

• Avoid intramuscular haloperidol in patients with known NMS history; intramuscular olanzapine, ziprasidone, or lorazepam are alternatives with separate cautions.^[1,6]
• Do not combine intramuscular olanzapine with parenteral benzodiazepines because of respiratory depression risk.^[1]

Rechallenge after NMS

• Wait at least 2 weeks after full resolution; prefer a lower-potency or different-class antipsychotic; restart at low dose with slow titration and close monitoring; consider the necessity of antipsychotic versus alternatives.^[6]
• Document informed consent including the 30-50% recurrence risk.^[6]

Several long-running debates shape how clinicians prescribe and monitor for movement disorders, and none have a settled answer.

First-generation versus second-generation antipsychotics

• Early enthusiasm for second-generation antipsychotics as broadly "EPS-sparing" has been tempered by pragmatic trials, particularly CATIE and CUtLASS, which found smaller differences in extrapyramidal burden than initially expected outside of clozapine and quetiapine.^[5-6]
• High-potency first-generation agents (haloperidol, fluphenazine) continue to carry the greatest acute EPS and tardive risk, but several second-generation agents (risperidone, paliperidone) approach first-generation rates at higher doses.^[1,7]
• Olanzapine and quetiapine carry lower motor risk but substantially higher metabolic burden; the practical choice is rarely "safer" so much as "trading which harm."^[5,7]

Prophylactic anticholinergics

• Routine co-prescription of benztropine with high-potency antipsychotics reduces acute dystonia incidence but contributes to cognitive impairment, constipation, urinary retention, and possibly higher tardive dyskinesia risk over time.^[3,8]
• Guidelines vary: some recommend prophylaxis only in high-risk patients (young men, high-potency agents, prior dystonia history), while others avoid routine use entirely.^[1,3]
• The unresolved question is whether anticholinergic exposure independently worsens tardive outcomes or merely unmasks them when withdrawn.^[8,15]

VMAT2 inhibitor placement and access

• Valbenazine and deutetrabenazine have the strongest evidence base for tardive dyskinesia, but their cost and limited head-to-head data against switching antipsychotics, adding clozapine, or pursuing dose reduction leave their precise place in the algorithm contested.^[16-18]
• Whether VMAT2 inhibitors should be initiated before, after, or alongside antipsychotic optimization is not settled by current trials.^[16,18]
• Long-term tolerability and the impact of stopping VMAT2 therapy after sustained response remain inadequately studied.^[16-17]

NMS rechallenge and clozapine after NMS

• Whether and when to restart antipsychotics after NMS is not standardized; observational data suggest rechallenge with a lower-potency agent after at least two weeks of recovery is often successful, but recurrence rates of 10-30% are reported.^[10,19]
• Clozapine after NMS is controversial: some case series suggest favorable outcomes, others document recurrence, and the decision is typically individualized with explicit informed consent.^[10,20]

Serotonin syndrome diagnostic criteria

• The Hunter Serotonin Toxicity Criteria outperform the older Sternbach criteria in sensitivity and specificity, but neither is perfect, and mild cases blur with akathisia, withdrawal, and anticholinergic toxicity.^[11-12]
• Whether some "serotonin syndrome" cases on combined SSRI plus MAOI represent a distinct toxicity rather than a continuum is debated.^[11]

• Acute dystonia typically occurs within 4 days of antipsychotic initiation or dose escalation, is most common in young men on high-potency D2 antagonists, and responds rapidly to IM benztropine or diphenhydramine.^[2-3]
• Laryngeal dystonia is a life-threatening variant of acute dystonia requiring immediate parenteral anticholinergic treatment and airway readiness.^[3]
• Akathisia presents as subjective inner restlessness with objective motor restlessness, is frequently misdiagnosed as anxiety or psychotic agitation, and has been linked to increased suicide risk.^[4]
• First-line treatment for akathisia is propranolol 10-30 mg three times daily or dose reduction of the offending agent; benzodiazepines are second-line.^[4,8]
• Drug-induced parkinsonism is symmetric (unlike idiopathic Parkinson disease, which is typically asymmetric) and reversible over weeks to months after discontinuation.^[1,7]
• Tardive dyskinesia requires at least 1-3 months of cumulative antipsychotic exposure (1 month if age ≥ 60) and is characterized by involuntary orofacial, limb, or truncal movements that persist after drug discontinuation.^[15]
• Valbenazine and deutetrabenazine are FDA-approved VMAT2 inhibitors with high-certainty evidence for reducing tardive dyskinesia severity.^[16-17]
• The classic NMS tetrad is hyperthermia, severe muscle rigidity ("lead pipe"), autonomic instability, and altered mental status, typically evolving over 1-3 days with markedly elevated CK.^[9-10]
• NMS treatment is supportive (cooling, hydration, ICU monitoring) with discontinuation of the antipsychotic; dantrolene, bromocriptine, and amantadine have limited evidence and are reserved for severe or refractory cases.^[10,21]
• Serotonin syndrome distinguishes itself from NMS by clonus (especially inducible and ocular), hyperreflexia, and rapid onset within 24 hours of a serotonergic drug change.^[11-12]
• Hunter Criteria require a serotonergic agent plus one of: spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with agitation or diaphoresis; tremor and hyperreflexia; or hypertonia with temperature > 38°C plus ocular or inducible clonus.^[11]
• Cyproheptadine is the antidote of choice for moderate-to-severe serotonin syndrome at 12 mg initial dose then 2 mg every 2 hours.^[12]
• Lithium tremor is a fine, action tremor at therapeutic levels and a coarse tremor with ataxia at toxic levels; coarse tremor with confusion is an emergency.^[13]
• SSRI discontinuation syndrome (FINISH: Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal) typically emerges within days of stopping a short half-life agent like paroxetine or venlafaxine.^[14]
• Elderly patients develop tardive dyskinesia at roughly five times the rate of younger adults; in patients over 60, even brief antipsychotic exposure carries meaningful tardive risk.^[15]

No external funding. No conflicts of interest declared. Peer-review status: pending.